Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …

The development of a wide range of novel antineoplastic therapies has improved the
prognosis for patients with a wide range of malignancies, which has increased the number …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Cardiac diseases in the growing population of childhood cancer survivors are of major
concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy …

Survivors of childhood cancer are at risk of anthracycline-induced cardiotoxicity, which might
be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane …

Background Coronary artery disease (CAD) is a concerning late outcome for cancer
survivors. However, uniform surveillance guidelines are lacking. Aim To harmonise …

Aims Our aim was to assess the risk of cardiovascular disease (CVD) mortality in US 5-year
survivors of adolescent and young adult (AYA) cancer compared with those of the general …

Purpose of review Thoracic radiation therapy is an effective treatment for several
malignancies, such as Hodgkin's lymphoma and breast cancer. Over the years, however, the …

Background Heart failure is one of the most important late effects after treatment for cancer in
childhood. The goals of this study were to evaluate the risk of heart failure, temporal …